Clostridium difficile Infection

C. diff Pathogenesis - Spore Wars

• The Culprit: Gram +ve, spore-forming, anaerobic bacillus. Resilient spores drive transmission & relapse.
• Spore Lifecycle & Gut Invasion:
  • Ingestion of hardy spores (fecal-oral).
  • Spores survive stomach acid, germinate in colon post-antibiotic dysbiosis.
  • Vegetative cells colonize, multiply, release toxins.
• Key Virulence Factors - The Toxins: 📌 Toxins ABC
  • Toxin A (TcdA): Enterotoxin ("Aqua" - watery diarrhea). Causes inflammation, fluid secretion.
  • Toxin B (TcdB): Cytotoxin ("Bad" - more potent). Induces severe cytoskeletal damage, cell death.

    ⭐ Toxin B is 10x more potent than Toxin A in causing colonic mucosal damage.

  • Binary Toxin (CDT): ADP-ribosylating toxin ("Complicates"). In hypervirulent strains (e.g., NAP1/BI/027); enhances adherence, ↑ severity.
• Cellular Sabotage: Toxins A & B glucosylate Rho GTPases → actin disruption, cell death, breaks tight junctions → pseudomembranes.

CDI Clinical & Dx - Gut Check

• Clinical Spectrum:

  • Asymptomatic carriage to severe, fulminant disease.
  • Common: Watery diarrhea (≥3 loose stools in 24h), abdominal pain, low-grade fever, leukocytosis.
  • Severe: Pseudomembranous colitis, toxic megacolon, colonic perforation, sepsis, shock.

• Diagnostic Tests (Stool):

  • Glutamate Dehydrogenase (GDH) antigen: Sensitive, not specific (detects C. diff presence).
  • Toxin A/B EIA: Specific, less sensitive (detects toxin production).
  • Nucleic Acid Amplification Test (NAAT/PCR): Highly sensitive & specific for toxigenic C. diff genes (e.g., tcdA, tcdB).
  • Two-step algorithm common: GDH + Toxin EIA. If discordant, proceed to NAAT.

• Severity Assessment (e.g., IDSA/SHEA criteria for severe CDI):

  • WBC count > 15,000 cells/μL.
  • Serum Creatinine ≥ 1.5 mg/dL or an increase to >1.5x baseline.

⭐ The presence of pseudomembranes on colonoscopy is highly suggestive of CDI, but colonoscopy is not routinely recommended for diagnosis due to perforation risk and availability of non-invasive tests.

CDI Management - Eviction Notice

📌 VFM for initial therapy: Vancomycin, Fidaxomicin, Metronidazole.

• Initial Episode (Non-Severe):
  • Oral Vancomycin 125 mg QID x 10 days
  • OR Fidaxomicin 200 mg BID x 10 days
  • Metronidazole 500 mg TID x 10-14 days (if Vanco/Fida unavailable).
• Initial Episode (Severe/Fulminant):
  • Oral Vancomycin 125 mg QID (may ↑ to 500 mg QID if ileus).
  • PLUS IV Metronidazole 500 mg Q8H.
  • Consider rectal vancomycin if ileus.
• Recurrent CDI:
  • 1st Recurrence:
    • Standard 10-day Oral Vancomycin 125 mg QID, followed by prolonged tapered/pulsed regimen.
    • OR 10-day Fidaxomicin 200 mg BID.
  • 2nd+ Recurrence: (Choose one)
    • Vancomycin taper/pulse regimen.
    • Fidaxomicin 200 mg BID x 10 days (if not used extensively).
    • Fecal Microbiota Transplantation (FMT).
    • Bezlotoxumab (monoclonal antibody vs Toxin B, adjunct to standard antibiotics for prevention of further recurrence).

⭐ Fecal Microbiota Transplantation (FMT) has shown high efficacy (often >80-90%) in treating multiple recurrent CDI.

• Prevention & Control:
  • Hand hygiene: Soap & water (spores!).
  • Contact precautions: Gloves, gown.
  • Environmental disinfection: Sporicidal agents (e.g., bleach).
  • Antibiotic stewardship.

High‑Yield Points - ⚡ Biggest Takeaways

• Clostridioides difficile: Gram-positive, anaerobic, spore-forming bacillus causing antibiotic-associated diarrhea (AAD).
• Key virulence: Toxin A (enterotoxin) & Toxin B (cytotoxin) leading to pseudomembranous colitis.
• Risk factors: Antibiotic exposure (clindamycin, cephalosporins, fluoroquinolones), hospitalization, PPIs.
• Diagnosis: Stool NAAT/PCR for toxin genes (most sensitive) or toxin EIA.
• Treatment: Oral vancomycin or fidaxomicin. Metronidazole for mild, initial non-severe episodes.
• Prevention: Soap & water hand hygiene (spores resist alcohol), contact precautions, antibiotic stewardship.
• High recurrence rates; consider Fecal Microbiota Transplantation (FMT) for multiple refractory recurrences.